Stewart Vickrey
Psychiatric/Mental Health · Stanton, KYNPI 1982007431
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $54,535 of the $64,124 with a category attached, or 85.0%. AbbVie accounts for 92.4% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2021 at $24,633 and has fallen 99.4% since, to $145 in 2025. Among psychiatric/mental health clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $244.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$59K
- Neurocrine Biosciences, Inc.$2K
- Corium, LLC$947
- Supernus Pharmaceuticals, Inc.$398
- Teva Pharmaceuticals USA, Inc.$321
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$189
- plus $760 from 16 others
What the payments were for
- Consulting fees$4901%
- Speaking & faculty fees$54,53585%
- Travel & lodging$4,6897%
- Food & beverage$4,3517%
- Education$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,124 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $111,223 |
| VraylarCariprazine Hcl | 60 | $90,316 |
| Methylphenidate ErMethylphenidate Hcl | 15 | $1,520 |
| Duloxetine Hcl | 24 | $1,265 |
| Buspirone Hcl | 64 | $1,245 |
| Quetiapine Fumarate | 51 | $670 |
| Bupropion XlBupropion Hcl | 27 | $442 |
| Adderall XrDextroamphetamine/Amphetamine | 13 | $434 |
| Lamotrigine | 74 | $424 |
| Guanfacine Hcl ErGuanfacine Hcl | 22 | $332 |
| Trazodone Hcl | 43 | $237 |
| Memantine Hcl | 24 | $188 |
| Hydroxyzine Pamoate | 17 | $143 |
| Mirtazapine | 14 | $117 |
| Fluoxetine Hcl | 19 | $84 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $2,273 | $111,22314 claims |
| AbbVieVraylar | $59,236 | $90,31660 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Stanton
- Theresa WattsAshland$645K
- Rachel ColeHopkinsville$503K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
- Hope SmithHopkinsville$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.